← Human Trials & Peer-Reviewed Studies
Prognostic value of carbohydrate antigen 125 combined with N-terminal pro B-type natriuretic peptide in patients with acute heart failure: a prospective cohort study in Vietnam
Plain-language guide to PMID 40681999 (2025): observational study study of BNP (Nesiritide) in 316 patients.
Key Facts
- PMID
- 40681999
- Journal
- BMC cardiovascular disorders
- Year
- 2025
- Study type
- Observational Study
- Authors
- Truong CM et al. (4 authors)
- DOI
- 10.1186/s12872-025-04994-0
What This Study Did, in Plain Language
What Was Tested
Researchers studied BNP (Nesiritide) in this observational study publication.
This study aimed to evaluate the prognostic utility of CA125 in combination with N-terminal pro-B-type natriuretic peptide (NT-proBNP) for predicting cardiovascular mortality, all-cause mortality, and a composite outcome of all-cause mortality or rehospitalization due to heart failure in patients with AHF.
Why It Was Studied
Carbohydrate antigen 125 (CA125) is an emerging prognostic biomarker for acute heart failure (AHF).
Who Took Part
According to the abstract, 316 patients were involved.
By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.
This prospective observational study included 316 patients with AHF.
How the Study Was Run
The methods mention a period of 12 months.
Both CA125 and NT-proBNP levels were measured at the time of first admission.
Mortality and rehospitalization due to heart failure were recorded over a 12-month follow-up period.
What Was Measured
Topics PubMed links to this paper include Natriuretic Peptide, Brain, Heart Failure, CA-125 Antigen, Biomarkers, Peptide Fragments, Prognosis and Patient Readmission.
The authors tagged it with the keywords Acute heart failure, Carbohydrate antigen 125, N-terminal pro B-type natriuretic peptide, Prognostic value and Vietnam.
What This Means in Plain Language
This is a observational study of BNP (Nesiritide) in 316 patients over 12 months.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2025 (BMC cardiovascular disorders), a journal based in England.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.